Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT; Australian Ovarian Cancer Study; Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F. Xu H, et al. Among authors: simpkins f. iScience. 2024 May 15;27(7):109978. doi: 10.1016/j.isci.2024.109978. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021796 Free PMC article.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS. Barnicle A, et al. Among authors: simpkins f. Genome Med. 2024 Dec 18;16(1):145. doi: 10.1186/s13073-024-01413-5. Genome Med. 2024. PMID: 39695768 Free PMC article.
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.
Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, Rames MJ, Kim S, Guo X, Jameson N, de Jong PR, Yea S, Harford L, Li J, Mathews CA, Doroshow DB, Charles VJ, Kim D, Fischer K, Samatar AA, Jubb A, Bunker KD, Blackwell K, Simpkins F, Meric-Bernstam F, Mills GB, Harismendy O, Ma J, Lackner MR. Kim D, et al. Among authors: simpkins f. NPJ Precis Oncol. 2025 Jan 4;9(1):3. doi: 10.1038/s41698-024-00787-4. NPJ Precis Oncol. 2025. PMID: 39755818 Free PMC article.
Telehealth utilization in gynecologic oncology clinical trials.
Andriani L, Oh J, McMinn E, Gleason E, Koelper NC, Chittams J, Simpkins F, Ko EM. Andriani L, et al. Among authors: simpkins f. Gynecol Oncol. 2023 Oct;177:103-108. doi: 10.1016/j.ygyno.2023.08.011. Epub 2023 Aug 31. Gynecol Oncol. 2023. PMID: 37659265 Free PMC article.
Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Taylor RN, Barnicle A, Munley JY, Aghajanian C. Liu YL, et al. Among authors: simpkins f. Cancer. 2025 Jan 15;131(2):e35707. doi: 10.1002/cncr.35707. Cancer. 2025. PMID: 39817648 Free PMC article. Clinical Trial.
72 results